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SUMMARY · Over the last 120 years, a great progress has been made in the diagnosis and treat-
ment of pulmonary tuberculosis. In Western Europe, the incidence of pulmonary tuberculosis was
700/100,000 at the beginning, and 10-20/100,000 at the end of the 20th century. Changes in the
epidemiological pattern entailed modifications in the clinical picture of pulmonary tuberculosis over
the mentioned period of time, so that at the end of the century (and millennium) four forms of the
disease could be defined: 1) active pulmonary tuberculosis in patients with post-tuberculosis sequels;
2) active pulmonary tuberculosis not associated with other diseases; 3) active pulmonary tuberculosis
associated with chronic diseases; and 4) active pulmonary tuberculosis in immunocompromised pa-
tients. It is emphasized that an increase in the number of group 3 and 4 active pulmonary tubercu-
losis patients should be expected in the third millennium. The detection and management of these
patients are difficult and complex. The detection of pulmonary tuberculosis is relatively late, while
the treatment often fails and leads to development of resistant Mycobacterium tuberculosis strains. The
existent problems encountered in the management of tuberculosis patients could be minimized by
the use of DOTS program, recommended by the World Health Organization and also by the Mi-
nistry of Health of the Republic of Croatia.
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Introduction
In the last 120 years, the diagnosis and treatment of
pulmonary tuberculosis have seen considerable advance-
ment.This progress has primarily been owing to the leading
figures as R. Koch, who discovered Mycobacterium (M.)
tuberculosis in 1882; K. Röntgen, who discovered x-rays in
1895; Calmette and Guerin, who reported on the discov-
ery of tuberculosis vaccine in 1924; Waksman, who dis-
covered streptomycin in 1944; and Robitzek and Salikof,
who reported on the discovery of isoniazid in 1952. These
ingenious discoveries have certainly contributed to the
decrease in the incidence of tuberculosis in Western Eu-
rope from 700/100,000 at the beginning to 10-20/
100,000 at the end of the 20th century1. In the ’80s, a low
incidence of pulmonary tuberculosis was recorded in the
Western countries, having given rise to hope it would not
present a medical and public health problem in the third
millennium. Misled by this line of reasoning, the anti-
tuberculotic care service was dissolved in the USA in
1985, which turned out to be a mistake. Pulmonary tuber-
culosis surveillance was soon lost, entailing epidemics in
particular cities, especially among HIV infected individu-
als, with consequential rapid development of resistant
myocobacteria2. Now, the global situation with pulmonary
tuberculosis is by no means good, as one third of the popu-
lation are infected with M. tuberculosis, 50 million of them
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with resistant agents. About 10 million people are affected
with, and about 3 million die from pulmonary tubercu-
losis every year. The number of individuals affected with
pulmonary tuberculosis has been anticipated to increase
in the next 10 years, primarily due to the rising number
of immunocompromised patients such as those with HIV
infection, transplanted organs, malignant diseases, on
chronic dialysis, and on immunosuppressive therapy3,4.
Changes in the epidemiological pattern during the last
hundred years entailed modifications also in the clinical
picture of pulmonary tuberculosis. Thus, the clinical pic-
ture of pulmonary tuberculosis at the beginning of the 20th
century differed substantially from the clinical picture of
the disease observed today, and can be basically classified
into four forms: 1) active pulmonary tuberculosis in pa-
tients with post-tuberculosis sequels; 2) active pulmonary
tuberculosis not associated with other diseases; 3) active
pulmonary tuberculosis associated with chronic diseases;
and 4) active pulmonary tuberculosis in immunocompro-
mised patients.
1) Active Pulmonary Tuberculosis in Patients with
Post-tuberculosis Sequels
This group includes elderly patients who underwent
treatment with a collapse method (thoracoplasty, extra-
pleural pneumolysis, phrenicotomy, artificial pneumothorax)
some 50 years ago. At present, their clinical picture is gen-
erally predominated by chronic obstructive pulmonary dis-
ease (COPD), chronic pulmonary heart, and chronic respi-
ratory insufficiency. In these patients, pulmonary tubercu-
losis which may not always be easily demonstrable, may re-
activate at any moment. Tuberculosis reactivation is clini-
cally manifested with subfebrile body temperature, coughing,
excessive perspiration, loss of appetite, emaciation, and gen-
eral exhaustion. Auscultatory finding is non-characteristic,
while laboratory findings may show normal leukocyte count
and signs of anemia due to chronic infection. Radiologic di-
agnosis of reactivated pulmonary tuberculosis is hampered by
massive pathomorphological and anatomical changes of pul-
monary parenchyma and mediastinum. Therefore, computed
tomography (CT) of the thorax may occasionally be required,
as it can better differentiate recent changes from previous
lesions. Gallium scintigraphy can also be helpful in the di-
agnosis of pulmonary tuberculosis reactivation, because the
radioactive medim is accumulated in recent foci5. Reactiva-
tion of pulmonary tuberculosis is definitely demonstrated by
the finding of M. tuberculosis in sputum.
Current treatment of pulmonary tuberculosis includes
six-month 2 HRZE/4 HR+ (H = isoniazid; R = rifampi-
cin; E = ethambutol; S = streptomycin; Z = pyrazinamide)
regimen,  with dose reduction in elderly patients (H, 5
mg/kg; R, 450 mg; E, 20 mg/kg; Z, 1.5 g; S, 0.5 g)6. The
number of tuberculotic patients from this group is small,
and they will only sporadically be seen in the third mil-
lennium.
2) Active Pulmonary Tuberculosis not Associated
with Other Diseases
This group of pulmonary tuberculosis patients prevailed
in Europe until the introduction of antituberculotics. In
Croatia, their number was relatively high until the late ’70s.
These mostly were young and middle-aged patients with exu-
dative forms (caseous pneumonia, cavernous disseminated
tuberculosis), productive forms (fibroulcerative tuberculosis,
fibroproductive tuberculosis), and hematogenous forms (mil-
iary tuberculosis). The exudative and hematogenous forms
usually presented with a clinical picture of acute disease (high
body temperature, dyspnea, coughing, hemoptysis, emaciation,
weight loss, etc.), as differentiated from the productive forms
that proceeded subclinically with mild symptoms. Such ‘pure’
forms of pulmonary tuberculosis have recently been ever less
frequently encountered, anticipating their further reduction
in the next millennium. In the treatment for these types of
pulmonary tuberculosis, the six-month 2 HRZE/4 HR regi-
men is used.The post-tuberculosis sequels are minimal pro-
vided the treatment has been properly performed. However,
inappropriate treatment results in chronic BK positivity, fre-
quently with resistant M. tuberculosis strains.
3) Active Pulmonary Tuberculosis Associated with
Chronic Diseases
This group of patients generally includes elderly indi-
viduals with poor socioeconomic status, poor home care
and inadequate family concern, in whom two, three or
more organic systems have been seriously impaired (e.g.,
chronic cardiac, renal, hepatic, pulmonary, psychiatric
diseases, diabetes mellitus, alcoholism, rheumatism, and
stroke). In these patients, the symptoms of pulmonary
tuberculosis overlap with the symptoms of other chronic
diseases, thus it is no surprise that they are initially man-
aged at internal wards, while the diagnosis of pulmonary
tuberculosis is made relatively late. Clinically, they present
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general fatigue, subfebrile body temperature persisting for
weeks or months, thinning, and of respiratory symptoms
coughing and occasionally hemoptysis. The diagnosis is
quite difficult to make due to the patient noncooperativity.
Radiologic finding is not as characteristic as in the former
two groups. The specific pathomorphological substrate
may be masked by pulmonary alterations due to other
chronic diseases such as chronic cardiac arrest, uremic
lungs, rheumatic infiltration, abscessing pneumonia in
alcoholics, pleural effusion in cirrhosis, etc. Thoracic CT
and gallium scintigraphy may help make the diagnosis5,7.
The treatment is primarily based on the bacteriologic veri-
fication of M. tuberculosis; very rarely, antituberculotics are
administered ex iuvantibus (on the basis of clinical pic-
ture and laboratory findings), because the addition of
three or four drugs in a chronic patient already taking a
number of medicaments means a considerable additional
load. In these patients, the antituberculotic therapy is by
no means easy to administer, and may sometimes even
prove unsuccessful. The patients frequently show low
medication compliance or even refuse it on the excuse
of being ‘heavy’. Side effects and complications may de-
velop requiring therapy discontinuation, which is the
easiest way for the development of resistant strains8.
Attention should especially be paid to the treatment of
active pulmonary tuberculosis in patients with hepatic
and renal insufficiency.
Pulmonary tuberculosis in patients with liver cirrho-
sis, hepatitis and icterus is treated with three nonhepato-
toxic drugs: streptomycin 1.0 g (0.75 g) per day, to a total
of 60 g; ethambutol 25 mg/kg/day; and Terizidon 3 cap-
sules a 250 mg. Isoniazid (5 mg/kg) and rifampicin (450
mg) should be introduced as soon as possible, however, if
it is not possible due to pathologic liver findings, quino-
lones are added to therapy (ofloxacin, ciprofloxacin). The
treatment is performed for 9-12 months9.
There still are some controversies concerning the treat-
ment of pulmonary tuberculosis in patients with chronic
renal insufficiency. Some authors consider that the dose
of antituberculotics should be reduced according to crea-
tinine clearance levels, whereas others suggest that there
is no need of dose adjustment, only the drugs should be
taken intermittently. This especially holds for nephrotoxic
drugs such as streptomycin, pyrazinamide and ethambu-
tol. Rifampicin is excreted by the liver, therefore it should
be administered in total dose every day, and isoniazid in
a dose of 300 mg/day on five days of the week. Accord-
ingly, the antituberculotic medication schedule in patients
with renal insufficiency is as follows:
· isoniazid · 300 mg on 5 days of week for 6 months
· rifampicin · 600 mg (450 mg) per day for 6 months
· ethambutol · 25 mg/kg 3x per week for 2-3 months
· pyrazinamide · 1.5-2.0 g 3x per week for 2-3 months
In patients on chronic dialysis, a total dose of antitu-
berculotics is administered 6 h before dialysis10.
In chronic cardiac patients with active pulmonary tu-
berculosis, care should be taken of possible interactions of
isoniazid and rifampicin with cardiac agents. Rifampicin
diminishes the pharmacologic effect of aminophylline,
beta-blockers, calcium antagonists and digitalis; isoniazid
increases the level of aminophylline; and propranolol slows
down the isoniazid breakdown.
4) Active Pulmonary Tuberculosis in Immunocom-
promised Patients
This group includes patients with HIV infection and
clinical picture of AIDS on long-term immunosuppres-
sive therapy (corticosteroids, cyclosporin, etc.), organ
transplantation, rheumatoid arthritis, immunoproliferati-
ve diseases, etc.
Patients with inactive pulmonary tuberculosis and sub-
sequent HIV infection soon progress to active pulmonary
tuberculosis, while patients with HIV infection and with-
out pulmonary tuberculosis easily acquire M. tuberculosis
infection from the bacillus expectorating subjects11. The
reason is the same in both cases. HIV infection impairs
immunity and weakens the body’s mechanisms of defense,
thus allowing for the infection to develop. It is considered
that in HIV-infected individuals, the infection with
tuberculotic (M. tuberculosis) and nontuberculotic myco-
bacteria (M. avium/intracellulare complex (MAC) occurs
when the CD4+ count falls below 100/mm3.12,13 The cli-
nical picture of pulmonary tuberculosis in HIV-infected
patients differs substantially from the usual clinical pic-
ture of the disease. Clinically, general symptoms (febrility,
thinning, diarrhea, fungal infections, herpes zoster) and
generalized lymph node enlargement predominate; mil-
iary tuberculosis is frequently present; and atypical local-
izations of tuberculous foci such as tuberculoma of the
brain, spleen, thorax, etc. are by no means infrequent. Ra-
diologic finding is atypical, regularly showing mediasti-
nal lymphonodi, basal infiltrations tending to migrate, and
pleural effusions, while cavernization is rarely observed.
The diagnosis of tuberculosis is made on the basis of posi-
tive M. tuberculosis in the sputum, blood, effusion and
other specimens, and histologic analysis of the compro-
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mised tissue. The treatment as a rule consists of the six-
month regimen with four ATL in the first two months (2
HRZE), followed by two drugs (4 HR) for another four
months, or according to some authors for six months
postnegativization.
Patients with active pulmonary tuberculosis associated
with chronic diseases and HIV infection are highly sus-
ceptible to the development of resistant M. tuberculosis
strains, which may cause complete therapeutic failure14.
In most cases, it is secondary resistance, rarely natural or
primary resistance. Secondary resistance develops during
the course of therapy, due to an error made by the physi-
cian, patient, or both. In case of monoresistance, antitu-
berculotics to which the causative agent is sensitive are
prescribed. The situation is more difficult in polyresis-
tance, and very difficult in multiresistance (MDR)15. In
these cases, quinolones (ofloxacin, ciprofloxacin), amino-
glycosides (amikacin), or macrolides (clarithromycin)
should be introduced in therapy16.
The management of resistant tuberculosis is expensive
for the society, painstaking for the patient, and difficult
and risky for the medical personnel involved, while the
results of treatment are quite poor. In Croatia, there are
2.2% of patients resistant to one or more antituberculotics,
0.5% of them relating to multiresistant strains. Therapeu-
tically and prognostically, multiresistant patients gener-
ally fall into the same category with AIDS patients, how-
ever, the issue of resistant tuberculosis has by no means
been given due consideration as AIDS at the national
level, although the two diseases bear an equal life-threat-
ening risk and lethality. Therefore, health care service
should be so organized as to prevent the development of
resistant M. tuberculosis strains, which could be achieved
by implementing the DOTS program, recommended by
the World Health Organization and Ministry of Health
of the Republic of Croatia17-19.
In immunocompromised patients, beside M. tubercu-
losis infection, infections with nontuberculous human
pathogenic ubiquitary mycobacteria may occur, which
clinically and radiologically bear great semblance with
active tuberculosis. Among nontuberculous mycobacteria,
MAC is most commonly reported. These infections are
more common in elderly patients. The disease is chronic,
manifesting with coughing, expectoration, febrility, and
faint auscultation finding of the lungs. Radiologic alter-
ations are similar to those seen in pulmonary tuberculo-
sis, visualized as subpleural and subapical infiltrates with
a tendency to disintegration and fibrozation. The diagno-
sis is made on the basis of bacteriologic verification of
MAC in the sputum or blood in case of a disseminated
form of disease. MAC infection should be suspected when
antituberculotic therapy fails in the presence of clinical
and radiologic findings indicative of tuberculosis20. The
treatment is long-term, performed for at least 12 months
with five drugs, including two basic (rifampicin and
ethambutol) and three adjuvant (clarithromycin, ami-
kacin, ciprofloxacin, azithromycin, clafamizin) drugs, and
can be prolonged for up to 24 months10.
In conclusion, ‘comfortable’ management of pulmo-
nary tuberculosis will have been left behind in the second
millennium. In the third millennium, the occurrence of
pulmonary tuberculosis asssociated with other chronic
diseases also in immunocompromised patients should be
expected, which will require much patience and good in-
ternist knowledge from pulmonologists. We do believe
that pulmonologists will find way to manage this new M.
tuberculosis challenge successfully.
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Saæetak
KLINI»KA SLIKA PLUÆNE TUBERKULOZE NA KRAJU DRUGOG TISUÆLJEÆA
I. Grbac, S. SmolËiÊ, D. Jurman i S. Broz
U posljednjih 120 godina uËinjen je velik napredak u dijagnostici i lijeËenju pluÊne tuberkuloze. Incidencija tuberkuloze
u zapadnoj Europi na poËetku bila je 700/100.000, a na kraju stoljeÊa 10-20/100.000. Promjenom epidemiolo¹ke situacije kroz
navedeno razdoblje mijenjala se i kliniËka slika tuberkuloze, koja bi se na kraju stoljeÊa (tisuÊljeÊa) mogla definirati u Ëetiri
oblika: 1. aktivna pluÊna tuberkuloza u bolesnika s poslijetuberkuloznim posljedicama; 2. aktivna pluÊna tuberkuloza bez drugih
popratnih bolesti; 3. aktivna pluÊna tuberkuloza s popratnim kroniËnim bolestima; i 4. aktivna pluÊna tuberkuloza u imu-
nokompromitiranih bolesnika. IstiËe se kako u treÊem tisuÊljeÊu treba oËekivati porast bolesnika s aktivnom pluÊnom tuberkulozom
treÊe i Ëetvrte skupine. Napominje se kako je otkrivanje i lijeËenje ovih bolesnika te¹ko i sloæeno. Tuberkuloza se otkriva
relativno kasno, lijeËenje je Ëesto neuspje¹no i brzo dovodi do razvoja rezistentnih sojeva Mycobacterium tuberculosis. Primjenom
programa DOTS koji preporuËa Svjetska zdravstvena organizacija i Ministarstvo zdravstva Republike Hrvatske postojeÊi bi
se problemi u zbrinjavanju tuberkuloznih bolesnika mogli svesti na najmanju moguÊu mjeru.
KljuËne rijeËi: tuberkuloza pluÊna, epidemiologija; tuberkuloza pluÊna, prevencija i suzbijanje
